Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01682902 · ClinicalTrials.gov registry record · Phase 1
A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT01682902 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 43 participants.
The verdict
NCT01682902, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of the trial is to evaluate continuous subcutaneous infusion of NN1218 formulations and NovoLog® in subjects with type 1 diabetes.
Interventions
- DRUG insulin aspart
- DRUG Faster-acting insulin aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01682902
The ClinicalTrials.gov registry entry for NCT01682902 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin aspart is the first listed.
NCT01682902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01682902 about?
NCT01682902 is a clinical study titled "A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes". This trial is conducted in the United States of America (USA). The aim of the trial is to evaluate continuous subcutaneous infusion of NN1218 formulations and NovoLog® in subjects with type 1 diabetes.
What is the current status of trial NCT01682902?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2012-09. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01682902?
The interventions under investigation include: insulin aspart (DRUG), Faster-acting insulin aspart (DRUG).
Who is sponsoring clinical trial NCT01682902?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.